- Home
- ZEPP vs BOLD Comparison
ZEPP vs BOLD Comparison
Compare ZEPP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- BOLD
- Stock Information
- Founded
- ZEPP 2013
- BOLD 2018
- Country
- ZEPP China
- BOLD United States
- Employees
- ZEPP N/A
- BOLD N/A
- Industry
- ZEPP Computer Manufacturing
- BOLD
- Sector
- ZEPP Technology
- BOLD
- Exchange
- ZEPP Nasdaq
- BOLD Nasdaq
- Market Cap
- ZEPP 37.1M
- BOLD 30.3M
- IPO Year
- ZEPP N/A
- BOLD 2024
- Fundamental
- Price
- ZEPP $2.53
- BOLD $1.44
- Analyst Decision
- ZEPP
- BOLD Hold
- Analyst Count
- ZEPP 0
- BOLD 1
- Target Price
- ZEPP N/A
- BOLD N/A
- AVG Volume (30 Days)
- ZEPP 14.6K
- BOLD 61.2K
- Earning Date
- ZEPP 05-19-2025
- BOLD 05-09-2025
- Dividend Yield
- ZEPP N/A
- BOLD N/A
- EPS Growth
- ZEPP N/A
- BOLD N/A
- EPS
- ZEPP N/A
- BOLD N/A
- Revenue
- ZEPP $182,603,000.00
- BOLD N/A
- Revenue This Year
- ZEPP $758.69
- BOLD N/A
- Revenue Next Year
- ZEPP N/A
- BOLD N/A
- P/E Ratio
- ZEPP N/A
- BOLD N/A
- Revenue Growth
- ZEPP N/A
- BOLD N/A
- 52 Week Low
- ZEPP $2.06
- BOLD $1.06
- 52 Week High
- ZEPP $4.38
- BOLD $12.26
- Technical
- Relative Strength Index (RSI)
- ZEPP 44.78
- BOLD N/A
- Support Level
- ZEPP $2.51
- BOLD N/A
- Resistance Level
- ZEPP $2.67
- BOLD N/A
- Average True Range (ATR)
- ZEPP 0.17
- BOLD 0.00
- MACD
- ZEPP 0.01
- BOLD 0.00
- Stochastic Oscillator
- ZEPP 13.04
- BOLD 0.00
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in two segments: Xiaomi Wearable Products and Self-branded products & others. The product portfolio includes smartwatches and fitness bands. The majority is from Self-branded products & other segments. It generates majority of the revenue from Xiaomi Wearable Products segment.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.